July 27, 2022 - NaturalAntibody, the bioinformatics company accelerating antibody discovery with AI-based products for the pharmaceutical industry, has released AbStudio - a web-based solution that allows teams to discover antibody-based drug candidates to speed up research decision-making, bringing new therapeutics to market faster.
Using AbStudio, scientists can check if a given sequence was observed in any of the covered databases (patents, scientific literature, NGS, GenBank, and others), find a similar sequence with legal protection, and employ the data for predictive tasks such as mapping the mutational diversity of antibodies.
“AbStudio is a direct answer to our customers’ needs. From the beginning, NaturalAntibody was focused on acquiring high-quality antibody-specific data and designing predictive analytical tools. It quickly turned out that researchers need user-friendly solutions that offer hassle-free access to antibody data,” said Dr. Sonia Wróbel, Senior Product Manager at Natural Antibody.
“Scientists can save a lot of time on collating antibody-specific datasets with AbStudio. The platform offers ready-made data collection pipelines with fresh and regularly updated datasets. This allows teams to check if a given sequence was observed in any of the covered databases (patents, scientific literature, NGS, GenBank, and others), find a similar sequence with legal protection, and explore the mutational diversity of antibodies. This saves considerable amounts of time,”
said Dr. Konrad Krawczyk, co-founder and Chief Executive Officer at NaturalAntibody.
The Interactive Antibody Database is a comprehensive collection of antibody sequences and metadata from heterogeneous public sources. It covers the primary major outlets of antibody sequence information from Next Generation Sequencing (NGS) repositories, patents, structures, NCBI (e.g., GenBank, SRA), and manually curated antibodies.
The module helps teams to check if a given sequence was observed in any of the heterogeneous databases, find similar sequences with legal protection, and explore the mutational diversity and the disease/vaccine context of sequences.
AbStudio is the result of close collaboration with biotechnology companies, pharmaceutical enterprises, and Contract Research Organizations (CROs) specializing in antibody discovery and development. Continuous feedback from clients and NaturalAntibody’s cooperation with key partners, such as Icosagen Cell Factory, enabled the team to refine AbStudio with “prediction-first” experimental data for machine learning analytics.
“Having continuous feedback between the algorithm results and actual laboratory experiments ensures the highest quality of solutions proposed in AbStudio. Based on artificial intelligence algorithms, solutions like AbStudio open the door to the fast and precise analysis of the properties of experimental antibodies. Our goal is to continue making high-throughput antibody data more accessible to everyone who can leverage it for the benefit of drug discovery,” said Kamil Sabatowski, Vice President of the Board at NaturalAntibody.